122 related articles for article (PubMed ID: 38387281)
21. GDF15 negatively regulates chemosensitivity via TGFBR2-AKT pathway-dependent metabolism in esophageal squamous cell carcinoma.
Du Y; Ma Y; Zhu Q; Fu Y; Li Y; Zhang Y; Li M; Feng F; Yuan P; Wang X
Front Med; 2023 Feb; 17(1):119-131. PubMed ID: 36525138
[TBL] [Abstract][Full Text] [Related]
22. RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.
Li DJ; Shi M; Wang Z
Thorac Cancer; 2016 Sep; 7(5):570-580. PubMed ID: 27766776
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel.
Yan J; Shi L; Lin S; Li Y
Bioengineered; 2021 Dec; 12(1):5334-5347. PubMed ID: 34415232
[TBL] [Abstract][Full Text] [Related]
24. HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2.
Li J; Sang M; Zheng Y; Meng L; Gu L; Li Z; Liu F; Wu Y; Li W; Shan B
Exp Cell Res; 2021 Dec; 409(1):112891. PubMed ID: 34688610
[TBL] [Abstract][Full Text] [Related]
25. PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming.
Ma Y; Zhang X; Han X; Hao Z; Ji R; Li J; Guo W; Zhang Y; Guan F; Ma S
Mol Carcinog; 2023 Jun; 62(6):866-881. PubMed ID: 36988347
[TBL] [Abstract][Full Text] [Related]
26. Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma.
Zhang S; Tang W; Weng S; Liu X; Rao B; Gu J; Chen S; Wang Q; Shen X; Xue R; Dong L
Oncotarget; 2014 Aug; 5(16):7183-97. PubMed ID: 25216531
[TBL] [Abstract][Full Text] [Related]
27. Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer.
Sawayama H; Ogata Y; Ishimoto T; Mima K; Hiyoshi Y; Iwatsuki M; Baba Y; Miyamoto Y; Yoshida N; Baba H
Cancer Sci; 2019 May; 110(5):1705-1714. PubMed ID: 30861255
[TBL] [Abstract][Full Text] [Related]
28. Krüppel-Like Factor 4 Enhances Sensitivity of Cisplatin to Esophageal Squamous Cell Carcinoma (ESCC) Cells.
Chen C; Ma Z; Zhang H; Liu X; Yu Z
Med Sci Monit; 2017 Jul; 23():3353-3359. PubMed ID: 28694421
[TBL] [Abstract][Full Text] [Related]
29. RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes.
Zeng RJ; Zheng CW; Gu JE; Zhang HX; Xie L; Xu LY; Li EM
Mol Oncol; 2019 Sep; 13(9):2010-2030. PubMed ID: 31314174
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis.
Liu H; Zhang J; Luo X; Zeng M; Xu L; Zhang Q; Liu H; Guo J; Xu L
Oncol Res; 2020 Feb; 28(1):65-73. PubMed ID: 31558183
[TBL] [Abstract][Full Text] [Related]
31. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.
Lv L; Wang SC; Mo JY; Huang KL; Xu ML; Liu J
Biochem Biophys Res Commun; 2022 Jan; 586():129-136. PubMed ID: 34839191
[TBL] [Abstract][Full Text] [Related]
32. Y-box-binding protein 1 promotes tumor progression and inhibits cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Xu J; Hu Z
Biomed Pharmacother; 2016 Apr; 79():17-22. PubMed ID: 27044807
[TBL] [Abstract][Full Text] [Related]
33. Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin Pathway.
Fujikawa M; Koma YI; Hosono M; Urakawa N; Tanigawa K; Shimizu M; Kodama T; Sakamoto H; Nishio M; Shigeoka M; Kakeji Y; Yokozaki H
Am J Pathol; 2021 Apr; 191(4):686-703. PubMed ID: 33460563
[TBL] [Abstract][Full Text] [Related]
34. miR-338-5p inhibits cell proliferation, colony formation, migration and cisplatin resistance in esophageal squamous cancer cells by targeting FERMT2.
Lin WC; Chen LH; Hsieh YC; Yang PW; Lai LC; Chuang EY; Lee JM; Tsai MH
Carcinogenesis; 2019 Jul; 40(7):883-892. PubMed ID: 30576425
[TBL] [Abstract][Full Text] [Related]
35. Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.
Wang F; Ding X; Wang T; Shan Z; Wang J; Wu S; Chi Y; Zhang Y; Lv Z; Wang L; Fan Q
PLoS One; 2017; 12(4):e0174276. PubMed ID: 28406985
[TBL] [Abstract][Full Text] [Related]
36. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
37. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2.
Zhang Z; Xiong R; Li C; Xu M; Guo M
Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):826-833. PubMed ID: 31287493
[TBL] [Abstract][Full Text] [Related]
38. Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1.
Huang XP; Li X; Situ MY; Huang LY; Wang JY; He TC; Yan QH; Xie XY; Zhang YJ; Gao YH; Li YH; Rong TH; Wang MR; Cai QQ; Fu JH
Cancer Lett; 2018 Feb; 414():294-300. PubMed ID: 29107111
[TBL] [Abstract][Full Text] [Related]
39. Role of Smac in determining the chemotherapeutic response of esophageal squamous cell carcinoma.
Xu Y; Zhou L; Huang J; Liu F; Yu J; Zhan Q; Zhang L; Zhao X
Clin Cancer Res; 2011 Aug; 17(16):5412-22. PubMed ID: 21676925
[TBL] [Abstract][Full Text] [Related]
40. Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma.
Murakami T; Shoji Y; Nishi T; Chang SC; Jachimowicz RD; Hoshimoto S; Ono S; Shiloh Y; Takeuchi H; Kitagawa Y; Hoon DSB; Bustos MA
Mol Oncol; 2021 Apr; 15(4):1069-1087. PubMed ID: 33605536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
